Vibostolimab

Generic Name: Vibostolimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2231305-30-7

Unique Ingredient Identifier: 5XO3JF0FEK

Background: Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation for High-Risk Melanoma

Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial for high-risk melanoma due to futility criteria. Patients are recommended to switch to KEYTRUDA monotherapy. Merck continues to explore novel treatments, including a lung cancer study with the coformulation.

Related Clinical Trials:

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy